The difference in surface phenotypes between cytotoxic lymphocytes induced in vivo by systemic administration of human recombinant interleukin-2 and lymphokine activated killer cells induced in vitro

Rosenstein, 1984, Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2, Cancer Res, 44, 1946 Grimm, 1982, Lymphokine-activated killer cell phenomenon, 155, 1823 Lotze, 1981, Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor, Cancer Res, 41, 4420 Mule, 1984, Adoptive immunotherapy of established pulmonary metastasis with LAK cells and recombinant interleukin-2, Science, 225, 1487, 10.1126/science.6332379 Mule, 1986, Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy, Cancer Res, 46, 676 Rosenberg, 1985, Regression of established pulmonary metastasis and subcutaneous tumor mediated by the systemic administration of high dose recombinant interleukin-2, J Exp Med, 161, 1169, 10.1084/jem.161.5.1169 Saijo, 1986, Reduction of pulmonary metastasis of B-16 melanoma by human recombinant interleukin-2 and lymphokine-activated killer cells in immunosuppressed C57BL/6 mice receiving anticancer agent, Gann, 77, 487 Saijo, 1986, In vivo augmentation of cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastasis in C57BL/6 mice by subcutaneous multiple injection of high dose human recombinant interleukin-2 (rIL-2), J Cancer Res Clin Oncol, 111, 182, 10.1007/BF00389231 Gillis, 1978, T cell growth factor: parameters of production and a quantitative microassay for activity, J Immunol, 120, 2027 Kasai, 1980, A glycolipid on the surface of mouse natural killer cells, Eur J Immunol, 10, 175, 10.1002/eji.1830100304 Kasai, 1980, In vivo effect of anti-asialoGM1 antibody on natural killer activity, Nature, 291, 334, 10.1038/291334a0 Itoh, 1985, Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL-2) in collaboration with interferon-γ (IFN-γ), J Immunol, 134, 3124 Rosenberg, 1982, In vivo administration of interleukin-2 enhances specific alloimmune responses, Transplantation, 35, 631, 10.1097/00007890-198306000-00024 Hefeneider, 1983, In vivo interleukin-2 administration augments the generation of alloreactive cytolytic lymphocytes and resident natural killer cells, J Immunol, 130, 222 Donohue, 1984, In vivo administration of purified Jurkat-derived interleukin-2 in mice, Cancer Res, 44, 1380 Mazumder, 1984, Successful immunotherapy of natural killer resistant established pulmonary melanoma metastasis by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2, J Exp Med, 159, 495, 10.1084/jem.159.2.495 Ettinghausen, 1985, Systemic administration of recombinant interleukin-2 stimulates in vivo lymphoid cell proliferation in tissues, J Immunol, 135, 1488 Rosenberg, 1985, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N Engl J Med, 313, 1485, 10.1056/NEJM198512053132327